# rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

> **NCT00053573** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 20 (actual)

## Conditions studied

- Glycogen Storage Disease Type II
- Pompe Disease
- Acid Maltase Deficiency Disease
- Glycogenosis 2

## Interventions

- **BIOLOGICAL:** Myozyme

## Key facts

- **NCT ID:** NCT00053573
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2006-07
- **Final completion:** 2006-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053573, "rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00053573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*